Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	102.19	105.76	113.45	102.29
Revenue Growth (YoY)	-8.42%	-6.78%	10.91%	-
Cost of Revenue	4.18	3.88	4.64	4.79
Gross Profit	98.01	101.87	108.81	97.5
Selling, General & Admin	75.66	73.62	75.82	71.61
Research & Development	13.01	12.02	13.78	16.69
Operating Expenses	88.67	85.64	89.6	88.29
Operating Income	9.34	16.23	19.21	9.2
Interest & Investment Income	1.55	1.55	1.04	0.73
Earnings From Equity Investments	-0.08	-0.04	-1.31	-0.25
Currency Exchange Gain (Loss)	-1.5	-1.5	-1.5	-4.9
Other Non Operating Income (Expenses)	2.16	6.95	-8.97	3.73
EBT Excluding Unusual Items	11.47	23.18	8.48	8.51
Gain (Loss) on Sale of Assets	0	-0.07	-3.34	-
Other Unusual Items	0.1	0.1	1	0.9
Pretax Income	11.58	23.22	-76.97	9.41
Income Tax Expense	2.84	5.32	8.52	5.1
Earnings From Continuing Operations	8.74	17.9	-85.48	4.31
Minority Interest in Earnings	-4.57	-5.81	-7.45	-2.01
Net Income	4.17	12.09	-92.93	2.3
Net Income to Common	4.17	12.09	-92.93	2.3
Shares Outstanding (Basic)	87	85	66	64
Shares Outstanding (Diluted)	102	102	66	76
Shares Change (YoY)	33.83%	55.39%	-13.02%	-
EPS (Basic)	0.05	0.14	-1.41	0.04
EPS (Diluted)	0.02	0.05	-1.41	0.03
Free Cash Flow	-0.08	-5.96	17.38	5.69
Free Cash Flow Per Share	-0.00	-0.06	0.26	0.07
Gross Margin	95.91%	96.33%	95.91%	95.31%
Operating Margin	9.14%	15.35%	16.93%	9.00%
Profit Margin	4.08%	11.43%	-81.92%	2.25%
Free Cash Flow Margin	-0.08%	-5.63%	15.32%	5.56%
EBITDA	11.46	17.82	20.33	10.33
EBITDA Margin	11.22%	16.85%	17.92%	10.10%
D&A For EBITDA	2.12	1.59	1.11	1.13
EBIT	9.34	16.23	19.21	9.2
EBIT Margin	9.14%	15.35%	16.93%	9.00%
Effective Tax Rate	24.54%	22.91%	-	54.16%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q